January 14, 2025

Even Low Levels of ctDNA May Be Linked to Recurrence Risk in Early Lung Cancer, Study Finds

A recent study published by Black et al in Nature Medicine has found that very low traces of circulating tumor DNA (ctDNA) may be linked to increased recurrence risk in patients with early-stage lung ...

The ASCO Post

January 14, 2025

Study Finds Travel Distance to Lung Cancer Screening Facilities Differs by Race and Ethnicity

Differences exist in distance to lung cancer screening facilities by race and ethnicity, and they can only partially be explained by rurality. These findings could inform the placement of future imagi...

The ASCO Post

January 14, 2025

ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer

Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer, according to groundb...

The ASCO Post

January 14, 2025

Metformin May Impact Immunotherapy in NSCLC

Metformin may strengthen the effects of immunotherapy and improve recurrence-free survival in patients with lung cancer with overweight or obesity, according to a recently published article in the Jou...

The ASCO Post

January 13, 2025

Investigators Have Uncovered Global Trends in Risk Factors Linked to Lung Cancer Mortality

Recent statistics showing reductions in lung cancer–related mortality may not address trends linked to tobacco use, air pollution, and asbestos exposure.

The ASCO Post

January 10, 2025

Primary Lung Tumor SBRT Followed by Mediastinal Chemoradiotherapy in Locally Advanced NSCLC

In a phase II trial reported in The Lancet Oncology, Heinzerling et al found that primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemoradiotherapy (with or...

The ASCO Post

January 10, 2025

ORACLE Test May Predict Survival in Early Stages of Lung Cancer

The ORACLE test may be capable of predicting lung cancer survival at the point of diagnosis more effectively than currently used clinical risk factors.

The ASCO Post

January 10, 2025

Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC

In a phase II trial reported in The Lancet Oncology, Heinzerling et al explored the efficacy of primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemotherapy...

The ASCO Post

January 12, 2024

Changing Medical Practice Through Translational Research Successes

Converting data and science into medical progress requires a strategic emphasis on work that matters to patients, either through imminent application to clinical practice or potentially transformative basic discoveries.

Cedars-Sinai Pulse